OBJECTIVE: The primary aim is to describe drug and alcohol trajectories in adults with schizophrenia. METHOD: Growth mixture models were used to examine disordered and non-disordered use and abstinence in the Clinical Antipsychotic Trials of Intervention Effectiveness study. RESULTS: Five classes - always abstinent; fluctuating use, abuse, and occasional abstinence; occasional (ab)use; stopped (ab)use; abusing - fit best. Overlap exists between always abstinent drug and alcohol classes; less overlap exists across other classes. CONCLUSION: There is heterogeneity in drug and alcohol use among adults with schizophrenia. The lack of overlap between classes, save always abstinent, suggests modeling drug and alcohol use separately.
OBJECTIVE: The primary aim is to describe drug and alcohol trajectories in adults with schizophrenia. METHOD: Growth mixture models were used to examine disordered and non-disordered use and abstinence in the Clinical Antipsychotic Trials of Intervention Effectiveness study. RESULTS: Five classes - always abstinent; fluctuating use, abuse, and occasional abstinence; occasional (ab)use; stopped (ab)use; abusing - fit best. Overlap exists between always abstinent drug and alcohol classes; less overlap exists across other classes. CONCLUSION: There is heterogeneity in drug and alcohol use among adults with schizophrenia. The lack of overlap between classes, save always abstinent, suggests modeling drug and alcohol use separately.
Authors: Jeffrey W Swanson; Marvin S Swartz; Richard A Van Dorn; Eric B Elbogen; H Ryan Wagner; Robert A Rosenheck; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman Journal: Arch Gen Psychiatry Date: 2006-05
Authors: Marvin S Swartz; H Ryan Wagner; Jeffrey W Swanson; T Scott Stroup; Joseph P McEvoy; Jose M Canive; Del D Miller; Fred Reimherr; Mark McGee; Ahsan Khan; Richard Van Dorn; Robert A Rosenheck; Jeffrey A Lieberman Journal: J Nerv Ment Dis Date: 2006-03 Impact factor: 2.254
Authors: Pál Czobor; Richard A Van Dorn; Leslie Citrome; Rene S Kahn; W Wolfgang Fleischhacker; Jan Volavka Journal: Eur Neuropsychopharmacol Date: 2015-04-30 Impact factor: 4.600